Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique.
Sjöberg Å, Lutz M, Tannergren C, Wingolf C, Borde A, Ungell AL. Sjöberg Å, et al. Among authors: tannergren c. Eur J Pharm Sci. 2013 Jan 23;48(1-2):166-80. doi: 10.1016/j.ejps.2012.10.007. Epub 2012 Oct 26. Eur J Pharm Sci. 2013. PMID: 23103351
Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity.
Tannergren C, Langguth P, Hoffmann KJ. Tannergren C, et al. Pharmazie. 2001 Apr;56(4):337-42. Pharmazie. 2001. PMID: 11338677
The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique.
Tannergren C, Knutson T, Knutson L, Lennernäs H. Tannergren C, et al. Br J Clin Pharmacol. 2003 Feb;55(2):182-90. doi: 10.1046/j.1365-2125.2003.01722.x. Br J Clin Pharmacol. 2003. PMID: 12580990 Free PMC article.
Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers.
Engman H, Tannergren C, Artursson P, Lennernäs H. Engman H, et al. Among authors: tannergren c. Eur J Pharm Sci. 2003 May;19(1):57-65. doi: 10.1016/s0928-0987(03)00065-4. Eur J Pharm Sci. 2003. PMID: 12729862
Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernäs H. Tannergren C, et al. Clin Pharmacol Ther. 2003 Nov;74(5):423-36. doi: 10.1016/S0009-9236(03)00238-8. Clin Pharmacol Ther. 2003. PMID: 14586383 Clinical Trial.
Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N, Tannergren C, Rungstad D, Lennernäs H. Petri N, et al. Among authors: tannergren c. Pharm Res. 2004 Aug;21(8):1398-404. doi: 10.1023/b:pham.0000036913.90332.b1. Pharm Res. 2004. PMID: 15359574
The effect of pancreatic and biliary depletion on the in vivo pharmacokinetics of digoxin in pigs.
Tannergren C, Evilevitch L, Pierzynowski S, Piedra JV, Weström B, Erlwanger K, Tatara M, Lennernäs H. Tannergren C, et al. Eur J Pharm Sci. 2006 Nov;29(3-4):198-204. doi: 10.1016/j.ejps.2006.06.009. Epub 2006 Jun 30. Eur J Pharm Sci. 2006. PMID: 16935480
Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
Tannergren C, Bergendal A, Lennernäs H, Abrahamsson B. Tannergren C, et al. Mol Pharm. 2009 Jan-Feb;6(1):60-73. doi: 10.1021/mp800261a. Mol Pharm. 2009. PMID: 19183105
In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, Abrahamsson B, Tannergren C. Sjögren E, et al. Among authors: tannergren c. Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019. Epub 2013 May 29. Eur J Pharm Sci. 2013. PMID: 23727464
PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjögren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J. Kostewicz ES, et al. Among authors: tannergren c. Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21. Eur J Pharm Sci. 2014. PMID: 24060672 Review.
35 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page